top of page

Search Results

Results found for "LASEREDD Therapeutics"

Posts (304)

  • Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics

    July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics

  • Why Intracellular Drugs May Hold the Key to GPCR Therapeutics

    diffusion, offset kinetics, and rebinding ✅ Real-world examples of how residence time—not potency—predicts therapeutic The slow-offset compound stays on target longer, maintains therapeutic effect as concentrations drop, DrugResidenceTime #AllostericModulation #CytosolicKinetics #PK #PD #CellPermeabilityAssays #PAMPA #Caco2 #TherapeuticKinetics

  • Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes

    adipose tissue size more effectively than exendin, suggesting that biased agonism can lead to distinct therapeutic In conclusion, biased agonism at the GLP-1R represents a promising strategy for optimizing therapeutic continues to grow, it is likely to play an increasingly important role in the design of next-generation therapeutics Christopoulos, Signalling bias in new drug discovery: detection, quantification and therapeutic impact Drucker, D.J., Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.  

View All

Other Pages (83)

  • Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer

    Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and

  • Dr. Nicolas Gilles | Dr. GPCR Ecosystem

    He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

  • Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem

    Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

View All

Events (2)

View All
bottom of page